Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dimethindene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 19/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 19/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 19/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethindene SCHEMBL18759 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| (S)-(+)-Dimethindene SCHEMBL30910954 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL30436315 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL19284560 | 1.00 | CHRM1 (1.00) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL1972832 | 0.90 | CHRM1 (0.82) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL29455130 | 0.90 | CHRM1 (0.82) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL359490 | 0.90 | CHRM1 (0.82) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL29887834 | 0.90 | CHRM1 (0.82) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Dimethindene SCHEMBL28142887 | 0.87 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL6276908 | 0.87 | HRH1 (1.00) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| EP-4057999-B1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-12-13 | — | — | EP | claimed |
| US-11819576-B2 | Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients | EVONIK OPERATIONS GMBH (DE) | 2023-11-21 | — | — | US | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| US-20230147853-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | EVONIK OPERATIONS GMBH (DE) | 2023-05-11 | — | — | US | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-3932389-B1 | COMPOSITION FOR THE TREATMENT AND PREVENTION OF AT LEAST ONE SYMPTOM OF A SECONDARY DISEASE ASSOCIATED WITH COVID-19 IN HUMANS | SCHMIDT WERNER (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20250367209-A1 | IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | SOUTHERN RES INST (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250327082-A1 | New C5a Binding Nucleic Acids | APTARION BIOTECH AG (DE) | 2025-10-23 | — | — | US | disclosed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| WO-2022258987-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| US-20220372453-A1 | NON-LTR-RETROELEMENT REVERSE TRANSCRIPTASE AND USES THEREOF | UNIV TEXAS (US) | 2022-11-24 | — | — | US | disclosed |
| EP-3474953-B1 | SUBSTANCE MIXTURE CONTAINING GLYCOSAMINOGLYCAN, METHOD FOR PRODUCING SAME AND USE OF SAME | FACH DR CHRISTIAN (DE) | 2022-11-16 | — | — | EP | disclosed |
| US-11492625-B2 | C5a binding nucleic acids | APTARION BIOTECH AG (DE) | 2022-11-08 | — | — | US | disclosed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | disclosed |
| CN-115065933-A | Video display method, system, terminal equipment and storage medium | 宁波华讯通信服务有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-11352611-B2 | Non-LTR-retroelement reverse transcriptase and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367209-A1 | IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | MAPT, SORBS1, TARDBP | HRH1 3313/4885CHRM1 3198/4885CHRM2 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.